Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform
Journal of Biomedical Materials Research Part A · 2026
DOI: 10.1002/jbma.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, 2026. Verfasst von Brittany A Payan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA. Hauptthemen laut MEDLINE: Glioblastoma, Hydrogels, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Center at Illinois, NIH HHS, Carl R. Woese Institute for Genomic Biology.
Abstract (Originalsprache)
Glioblastoma is the most common primary malignant brain tumor with a 5‐year survival rate < 5%. The standard of care involves surgical resection followed by treatment with the alkylating agent temozolomide (TMZ). GBM cells that evade surgery eventually become resistant to TMZ and lead to recurrence of tumors in patients. With only four drugs currently FDA‐approved for GBM treatment, there is a need for a clinically relevant model capable of accelerating the identification of new therapies. Microgels are microscale (~10–1000 μm) hydrogel particles that can be used to encapsulate cells in a tailorable 3D matrix. Microdroplets offer short diffusion lengths relative to conventional hydrogel constructs (> 1 mm) to limit spatial distributions of hypoxia and potentially screen therapeutics in a controlled and physiologically relevant environment. Here, we establish a method to encapsulate GBM cells in gelatin and polyethylene glycol (PEG) microgels. We show that microgel composition can affect cell morphology and further, that collections of GBM‐laden hydrogels can be used to quantify the effect of single versus metronomic doses of TMZ. GBM metabolic activity is maintained in microgel culture and GBM cells display drug response kinetics similar to previously established literature using macro‐scale hydrogel constructs. Finally, we show microgels can be integrated with a liquid handler to enable high‐throughput screening using cell‐laden microgels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Department of Molecular and Cellular Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Department Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- School of Chemical Sciences High-Throughput Screening Facility, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA.
- George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
ORCID-Profile: Brittany A Payan, Andrés J García
Förderung
- Cancer Center at Illinois
- NIH HHS
- Carl R. Woese Institute for Genomic Biology
- NCI NIH HHS
- NIDDK NIH HHS
- NIBIB NIH HHS
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Payan, B. A., De Leon, A. C. D., Anand, T., Thompson, G. B., Krishnamurthy, V. V., Mora-Boza, A., García, A. J., & Harley, B. A. C. (2026). Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform. Journal of Biomedical Materials Research Part A. https://doi.org/10.1002/jbma.70043
Vancouver
Payan BA, De Leon ACD, Anand T, Thompson GB, Krishnamurthy VV, Mora-Boza A, et al. Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform. Journal of Biomedical Materials Research Part A. 2026. doi:10.1002/jbma.70043
BibTeX
@article{Payan2026,
author = {Payan, Brittany A and De Leon, Annika Carrillo Diaz and Anand, Tejasvi and Thompson, Gunnar B and Krishnamurthy, Vishnu V and Mora-Boza, Ana and García, Andrés J and Harley, Brendan A C},
title = {Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform},
journal = {Journal of Biomedical Materials Research Part A},
year = {2026},
doi = {10.1002/jbma.70043}
}
EUVIMED